Resources
44 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/9/2022 (updated 3/27/2024)
IMPORTANCE Thousands of pregnant people with opioid use disorder (OUD) enter US jails annually,
yet their access to medications for OUD (MOUD) that meet the standard of care (methadone and/or
buprenorphine) is unknown.
OBJECTIVE To assess the availability of MOUD for the treatment of pregnant individuals with OUD
in US jails.
Posted 3/15/2022 (updated 3/27/2024)
Pre- Pregnancy fact sheet. Information for Providers
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 10/15/2023 (updated 3/27/2024)
The University of Rochester Recovery Center of Excellence, one of three FORHP-supported Rural Centers of Excellence on Substance Use Disorder, has developed comprehensive training on the treatment of opioid use disorder (OUD) in primary care. This no-cost training prepares providers and staff to deliver evidence-based care to patients. Continuing education credits are available.
Posted 8/2/2022 (updated 3/27/2024)
Innovative at their inception three decades ago, drug courts confront a practical and ethical obligation to reimagine some core practices and assumptions. A shifting legal and public health landscape means, for example, increased scrutiny of the courts’ focus on abstinence and mandated treatment, and the use of jail. This publication argues the most effective way for drug courts to evolve is by integrating the practices and principles of harm reduction
Posted 6/3/2022 (updated 3/27/2024)
During this session, Dr. Lopata discussed federal/HRSA investments focused on improving the health outcomes for and reducing health disparities among maternal and child health populations. More specifically, Dr. Lopata discussed the multiple programs/interventions funded by HRSA that together work (along with federal, state, regional, and local partners) to improve the prevention, screening, and treatment of opioid use disorder during pregnancy and Neonatal Abstinence Syndrome in the United States.
Posted 6/3/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of Medication-Assisted Treatment (MAT) retention was highlighted.
Posted 6/3/2022 (updated 3/27/2024)
This session shared recent trend data on opioid and methamphetamine use, overdose rates, and the prevalence of neonatal abstinence syndrome in rural places across the U.S. In addition, data was presented on who is treating opioid use disorder in rural places and on the health workforce providing mental health services for rural patients.
Posted 6/7/2022 (updated 3/27/2024)
This session highlighted the ways in which data from RCORP consortia are used, how service capacity and access have changed, and whether there is evidence that the health status of rural residents is improving. Additional data on telehealth utility, COVID-19 vaccination efforts, and drivers of MAT retention were highlighted. (Repeated from Day 1 Session 4A on Tuesday, April 5th).
Posted 3/7/2023 (updated 3/27/2024)
Although pregnancy is motivation for opioid use disorder treatment, there is a risk of relapsing after childbirth. Unpacking Perinatal Experiences with Opioid Use Disorder: Relapse Risk Implications studies the perinatal experiences that can inform clinical social workers and other health/behavioral health providers on when and how to provide support during this time period.